Risk Factors for Beta-lactam Target Non Attainment in Critically Ill Patients BETALACTACRIT
Risk Factors for Beta-lactam Target Non Attainment in Critically Ill Patients
Beta-lactams agents are time-dependent antibiotics. Their bactericidal effects are associated with the time spent above the minimal inhibitory concentration (MIC) of the bacteria. In ICU patients, many pathophysiological changes may occur, which significantly alter beta-lactam pharmacokinetics (increasing in distribution volume, hypoalbuminemia or change in glomerular filtration rate…), leading to antibiotic underexposure, which may explain some treatment failures and risk of emergence of a multi-resistant bacteria.
Many guidelines advocate to reach a fixed target for the steady-state free plasma concentration of beta-lactam between 4 and 8 times of the MIC. However, clinical evidences supporting that septic patients in ICU would benefit from such optimization remain low and contradictory, and use of surrogate MICs based on critical breakpoints instead of actual MICs are significant limitations in the description of beta-lactam exposure among ICU patients with sepsis.
In this study, the investigators aim to indentify profiles of intensive care unit patients which are more likely to be associated with pharmacological failure (< 4 time the MIC of the bacteria). The investigators also aim to identify association between failure and poor clinical outcome.
Study Overview
Status
Conditions
Detailed Description
The duration of patient participation extends from the inclusion visit (D1), to discharge from intensive care; if the participant is still in intensive care at D90, the last visit with data collection will be at D90. The maximum duration of participation in the study will therefore be 3 months.
Taking into account 3 months of set-up, 1 year of recruitment, 3 months of participant follow-up, 3 months of data processing and 3 months of interpretation, 2 years will be sufficient to carry out this project.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Saint-Brieuc, France, 22000
- FILLATRE
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Participant over 18 years of age.
- Hospitalized in intensive care unit.
- Bacterial infection documented by culture.
- Treatment with beta-lactam for less than 48 hours.
- Person not objecting to participation in the study. If the particpant is unable to receive the information, it will be given to a relative and his or her non-opposition will be collected; the patient's non opposition will be sought and collected as soon as his or her condition permits.
Exclusion Criteria:
- Measurement of MIC of the bacterium in question impossible.
- Patients allergic to beta-lactam antibiotics.
- Patients with an estimated hospital stay of less than 3 days.
- Participants with "complex" infectious sites: central nervous system infection, osteoarticular infection, etc.
- Patients already included in the present study on the occasion of a previous beta-lactam administration.
- Adult patients under legal protection (safeguard of justice, curatorship, guardianship), persons deprived of liberty.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Identify proportion of participant with betalactam underexposure in critically ill patients with sepsis and predictive parameters.
Time Frame: 25 months
|
Under-exposure to beta-lactam antibiotics is defined as a plasma concentration below 4x the MIC of the identified bacterium.
This concentration will be measured as residual in the case of discontinuous administration, or at equilibrium in the case of continuous administration.
This criterion is assessed between 48 and 72 hours after the start of antibiotic therapy.
Variables that will be assessed include age (in years), body mass index (in kg/m²), renal clearance (calculated with creatininemia, urinary creatininuria urinary volumeper day expressed in mL/min), SAPSII score (no unit), site of infection, modality of antibiotic administration (intermittent, continuous), time since first antibiotic injection (in hours), body temperature (in °C), SOFA score (no units), blood cell numeration (in cell/mL), coagulation parameters (in % of activity), protidemia (in g/L), lactates level (in mmol/L).
|
25 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Count the number of participants with poor clinical outcome and pharmacological failure (< 4 times the bacterial MIC).
Time Frame: 25 months
|
The secondary objective is to establish the association between under-exposure to betalactam antibiotics in ICU participants and their clinical outcome.
Pharmacological failure, defined as < 4 times the bacterial MIC, will be correlated with poor clinical outcome, up to and including death.
|
25 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Pierre FILLATRE, CENTRE HOSPITALIER SAINT-BRIEUC PAIMPOL TREGUIER REANIMATION
- Study Chair: Nicolas NESSELER, CHU RENNES REANIMATION CHIRURGIE THORACIQUE CARDIAQUE ET VASCULAIRE
- Study Chair: Yoann LAUNEY, CHU RENNES REANIMATION CHIRURGICALE
- Study Chair: Flora DELAMAIRE, CHU RENNES REANIMATION MEDICALE
- Study Chair: Guillaume RIEUL, CH BRETAGNE ATLANTIQUE REANIMATION
- Study Chair: Pierre BOUJU, ch bretagne sud atlantique REANIMATION
- Principal Investigator: Aurélien FREROU, CH ST MALO REANIMATION
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHSB-2022-08-P5-BETALACTACRIT
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.